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C. Fred LeMaistreThe only therapy with the potential to cure myelo-
dysplastic syndromes (MDS) is allogeneic hematopoi-
etic stem cell transplantation (HCT) from either
a related or unrelated donor. Despite recent approvals
by the Food and Drug Administration of 3 new agents
for the palliative treatment of MDS, the majority of
patients will not obtain long-term benefit, and will
ultimately die of their disease. Identifying which pa-
tients can benefit from HCT and understanding how
best to integrate transplantation into their treatment
plan is therefore critical in counseling patients with
MDS. The issue that now confronts the transplant
community and the patients we serve is that we can
neither conduct the studies most needed to improve
transplant outcomes or even be assured of offering
the option of curative therapy to the group of patients
who most often are in need.
The heterogeneous nature of MDS, the complex-
ities of the population most at risk for MDS, and the
risks associated with HCT frustrate our ability to
make clear recommendations to patients in what oth-
erwise would be a discussion of therapy with curative
intent versus palliation. The MDS are a diverse collec-
tion of disorders in which patients present with
sequelae of ineffective hematopoiesis. Although some
patients are asymptomatic, most present with signs
or symptoms of anemia accompanied by infection or
bleeding [1]. MDS becomes more common as we
age; although the overall MDS incidence is 3.3 per
100,000, the incidence in patients over 70 is between
15 and 50 per 100,000 [2]. With a median age at pre-
sentation of 76 years, comorbid diseases significantly
impact treatment options and outcomes. To further
complicate management of these patients, current
prognostic scoring systems are often poorly predictive
for individual patients.Texas Transplant Institute, San Antonio, Texas.
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transplant treatment options, and advances in our abil-
ity to treat older patients and those with comorbid
conditions renders timely the publication of the evi-
dence-based review of transplantation in MDS in this
issue of BBMT [3]. The multidisciplinary panel of
experts convened for this review is to be congratulated
on a complete evaluation of current evidence and
a transparent analysis leading to a series of treatment
recommendations in Table 3 of the review. Even
with these recommendations, it is clear we need to
know more. The panel further identifies 4 priority
areas for research as a guide for future studies: ‘‘(1)
the benefit of using alternative donor sources (eg,
cord blood; haploidentical family donors) for patients
without matched sibling or unrelated donors; (2) the
role and appropriate timing of allogeneic SCT in com-
bination with hypomethylating and immunomodula-
tory treatment regimens; (3) randomized trials
comparing the safety and efficacy of various novel
agents for treating MDS; and (4) the influence of the
various MDS treatment modalities on patient-re-
ported quality-of-life outcomes.’’
Current Medicare policies for reimbursement of
HCT for MDS now serve as the major obstacle in
addressing these research priorities. Worse still, we
cannot offer potentially curative therapy to Medicare
beneficiaries or other patients whose health insurance
policies follow Medicare guidelines because of practi-
cal concerns about reimbursement.
Medicare’s current National Coverage Determi-
nation (NCD) on HCT does not include allogeneic
transplant for MDS. The absence of a national policy
allows for coverage at the discretion of local Medicare
Contractor Medical Directors. TheMedicare contrac-
tors have not created explicit local policies, nor are
they likely to do so. Additionally, Medicare structure
and policies effectively exclude the type of medical
appeal process prior to treatment that is routinely
available to commercially insured patients. As a result,
the procedure is not only too expensive for hospitals to
risk nonpayment, but patients and their families
become at risk for self-payment if coverage is denied.
For patients whose insurance coverage is governed
by Medicare NCDs, HCT can only be assured when
and if MDS evolves to acute leukemia. This limitation133
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decreased likelihood of cure to receive definitive treat-
ment.We should consider whether this is an appropri-
ate policy.
The lack of extensive published data for transplan-
tation in patients over the age of 65 years with MDS is,
at least in part, a result of these funding policies.
Current data in a variety of hematologic diseases using
reduced intensity HCT for older patients and those
with comorbid conditions validate the safety and effec-
tiveness of the technique [4-6]. These observations and
the evidence for transplantation as curative therapy
detailed in the adjoining evidence-based review form
the foundation for changing the Centers for Medicare
andMedicaid Services policy. Building on this founda-
tion, preliminary data from a retrospective study of
over 1000 patients with MDS or acute myelogenous
leukemia (AML) transplanted between 1995 and
2005 were presented by the Center for International
Blood and Marrow Transplant Research at the recent
2008 American Society ofHematology annualmeeting
[7]. Patients were stratified according to age cohorts
for comparison: 40-54, 54-59, 60-64, and $65 years.
Multivariate analysis revealed no statistically signifi-
cant impact of age on treatment-related mortality,
relapse, or survival. The authors concluded that out-
comes for older adults undergoing allogeneic HCT
are not significantly different than for younger adults,
even after adjusting for multiple risk factors, and age
by itself should not be the limiting factor for proceed-
ing to allogeneic HCT in older patients with AML or
MDS.
The American Society of Blood and Marrow
Transplantation in partnership with the National
Marrow Donor Program have committed to address
the lack of a NCD for transplantation in MDS. A joint
committee of the 2 organizations has already accom-
plished much background work in preparation for
the initiation of a dialogue with the Centers for
Medicare and Medicaid Services (CMS). Their efforts
have been careful, methodic, and like the current re-
view, evidence-based. This initiative is important toMDS patients in the United States, and both the
American Society for Blood and Marrow Transplanta-
tion (ASBMT) and the National Marrow Donor Pro-
gram (NMDP) are to be commended for their
leadership.
Research designed to describe optimal treatment
strategies for patients with MDS is important, but
must not obscure a central point. Therapy with the po-
tential to cure MDS is now available. Reimbursement
policies that force patients and their physicians to
accept an increased risk of mortality and diminished
therapeutic benefit prior to accessing curative treat-
ment are ill-conceived and not acceptable.ACKNOWLEDGMENTS
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